* Watchdog recommends against Afinitor, Tasigna and Sprycel
* Limited data to back benefits of three pricey drugs - NICE
LONDON, Feb 9 Britain's cost-effectiveness
watchdog recommended against two expensive cancer drugs from
Novartis AG NOVN.VX and one from Bristol-Myers Squibb Co
(BMY.N) being used within the state-run health service.
The National Institute for Health and Clinical Excellence
(NICE) said on Tuesday it was unable to recommend Afinitor from
Novartis as a second-line treatment for kidney cancer, adding
there was limited data about how long it could extend life.
It also rebuffed the Switzerland-based company's Tasigna and
Bristol's Sprycel for chronic myeloid leukaemia in patients who
are intolerant to Glivec -- an older drug from Novartis --
stating evidence to support their effectiveness was "very poor"
and their cost was "extremely high".
"It would be heartening to hear that the pharmaceutical
company manufacturers are prepared to share some of the very
high cost of the drugs with the NHS (National Health Service),"
NICE director Peter Littlejohns said in a statement.
NICE, which has pioneered the analysis of cost-effectiveness
for new drugs, has struck several previous deals with companies
to reduce the cost of medicines before recommending them for use
in the NHS.
Its latest draft guidance is available for public
consultation before any final decisions are taken.
(Reporting by Ben Hirschler; Editing by David Holmes)